Trial reportNutrients2020
Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study.
Trial report in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Efficacy of weekly versus daily cholecalciferol for repleting serum vitamin D (25(OH)D) deficiency: A systematic review and meta-analysis of randomized controlled trials.Basic & clinical pharmacology & toxicology · 2024Pooled it
- Pooled it
- Dietary and Nutraceutical Interventions as an Adjunct to Non-Surgical Periodontal Therapy-A Systematic Review.Nutrients · 2023Pooled it
- The Dose-Response Effects of Vitamin DNutrients · 2026Trial
- Trial
- Trial
- Pharmacodynamics of Oral Cholecalciferol in Healthy Individuals with Vitamin D Deficiency: A Randomized Open-Label Study.Nutrients · 2021Trial
- Serum vitamin D levels in patients with lung metastases.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2026Article
- Daily Calcium and Vitamin D Supplementation as a Foundational Pillar in Osteoporosis Management: A Narrative Review.Nutrients · 2026Review
- Beyond bones: Revisiting the role of vitamin D in chronic liver disease.World journal of hepatology · 2025Review
- Rethinking Vitamin D Deficiency: Controversies and Practical Guidance for Clinical Management.Nutrients · 2025Review
- Vitamin D-is the sun enough for us?Nutrition & metabolism · 2025Review
- Vitamin D Deficiency in Young Elite Soccer Players Residing Permanently in Regions above 55 Degrees North Latitude.Journal of bone metabolism · 2025Article
- Does Systematic Use of Small Doses of Vitamin D Have Anti-Inflammatory Effects and Effectively Correct Deficiency Among Healthy Adults?Nutrients · 2025Article
- Clinical Pregnancy and Miscarriage Rates in relation to Vitamin D Supplementation among women with Hyper Androgenic PCOS: A prospective study.International journal of fertility & sterility · 2025Article
- 1,25‑Dihydroxyvitamin D3 mitigates the adipogenesis induced by bisphenol A in 3T3-L1 and hAMSC through miR-27-3p regulation.International journal of obesity (2005) · 2024Article
- Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine reviews · 2024Article
- Article
- Pharmacokinetics of vitamin dosage forms: A complete overview.Food science & nutrition · 2024Review
- Intervention Approaches in Studying the Response to Vitamin DNutrients · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundthe aim of this study was to investigate the pharmacokinetic (PK) and safety profile of high-dose vitamin D supplementation, comparing different schedules (daily, weekly, or bi-weekly) in an otherwise healthy vitamin D-deficient population. Methods
resultsmean 25 (OH)D plasma levels significantly increased from baseline 13.5 ± 3.7 ng/mL to peak values of 81.0 ± 15.0 ng/mL in Group A, 63.6 ± 7.9 ng/mL in Group B and 59.4 ± 12 ng/mL in Group C. On day 28, all subjects showed 25 (OH)D levels ≥ 20 ng/mL and 93.1% had 25 (OH)D levels ≥ 30 ng/mL. On day 56 and 84, all subjects had 25 (OH)D levels ≥ 30 ng/mL. No serious adverse events occurred during the study.
conclusionsnormalization of 25 (OH)D serum levels was quickly attained with all the studied regimens. A more refracted schedule provided a higher systemic 25 (OH)D exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.